Achieve Life Sciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-54.6M | $-39.8M | $-29.8M | $-42.4M | $-33.2M | $-14.7M | $-16.4M | $-12.7M |
| Depreciation & Amortization | $228.0K | $229.0K | $228.0K | $236.0K | $250.0K | $255.0K | — | — |
| Depreciation | — | — | — | — | $27.0K | $32.0K | $31.0K | $60.0K |
| Amortization | $200.0K | $200.0K | $200.0K | $200.0K | $200.0K | $200.0K | $200.0K | $200.0K |
| Stock-Based Compensation | $8.8M | $5.3M | $3.4M | $3.3M | $2.2M | $1.3M | $1.2M | $854.0K |
| Net Cash from Operating Activities | $-49.5M | $-29.8M | $-24.5M | $-37.6M | $-29.4M | $-13.5M | $-15.2M | $-10.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.0K | — | $21.0K | — | — | $17.0K | $53.0K | $46.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $6.1M | $-21.6M | $-21.0K | — | — | $-17.0K | $5.0M | $-5.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $51.5M | $48.5M | $15.3M | $19.3M | $36.6M | $32.7M | $17.3M | $19.8M |
| Net Change in Cash | $8.2M | $-2.8M | $-9.2M | $-18.3M | $7.2M | $19.2M | $7.1M | $4.0M |
| Free Cash Flow | $-49.5M | — | $-24.5M | — | — | $-13.5M | $-15.3M | $-10.7M |